BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Adlyfe Develops Blood Test To Provide Effective Way To Detect Mad Cow And Related Misfolded Protein Diseases


10/19/2005 5:09:29 PM

ROCKVILLE, Md., July 7 /PRNewswire/ -- Adlyfe, Inc., a privately held biotech company headquartered in Rockville, MD, has developed a sensitive blood test for protein folding diseases that could provide earlier diagnosis of deadly diseases such as Mad Cow disease. This announcement is timely given the recent report issued by the Department of Agriculture reporting the second confirmed case of Mad Cow Disease in the U.S. New results from this test and the breakthrough findings will be published in the Journal of Peptides.

The test, developed by Dr. Cindy Orser, VP of Research and Development with Adlyfe, is designed to detect misfolded proteins that cause neurological diseases including Mad Cow, Sheep Scrapie and Creutzfeldt-Jacob disease in humans -- all of which are fatal brain disorders. Adlyfe has 11 patents pending on the technology, which address other protein folding brain diseases such as Alzheimer's and Huntington's disease.

Alan S. Rudolph, CEO, said the test is based on using small, synthetic peptides that mimic protein folding. The synthetic peptides detect the build up of damaging proteins in blood before they accumulate in the brain. This accumulation is correlated to brain damage, disease symptoms, and eventual death. The novel test has been under development for three years under the support of the Defense Advanced Research Projects Agency and the National Institutes of Health. Adlyfe has demonstrated detection of prion diseases in brain tissue and blood of cattle, sheep, and humans in clinical laboratory sampling.

"We are very encouraged by the early results of our test which show we can detect disease in blood and tissue samples from animals and humans. We look forward to offering a new test for early detection and diagnosis of these debilitating diseases," Rudolph said in a statement.

About Adlyfe, Inc.: Adlyfe is a biotechnology company focused on novel blood diagnostics and therapeutics in Rockville, MD. Adlyfe develops blood diagnostic tests for early diagnosis and treatment of chronic brain 'wastings' diseases such as Mad Cow disease and Alzheimer's. The company is privately held and funded by NIH, DARPA and several other parties. For more information about Adlyfe, visit: http://www.adlyfe.com .

Adlyfe, Inc.

CONTACT: Alan S. Rudolph of Adlyfe, Inc., arudolph@adlyfe.com , or+1-301-424-8344, ext. 203



Read at BioSpace.com

Adlyfe
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES